| The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy B Muz, P De La Puente, F Azab, A Kareem Azab Hypoxia, 83-92, 2015 | 2245 | 2015 |
| Cell culture in autologous fibrin scaffolds for applications in tissue engineering P De la Puente, D Ludeña Experimental cell research 322 (1), 1-11, 2014 | 195 | 2014 |
| 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma P de la Puente, B Muz, RC Gilson, F Azab, M Luderer, J King, S Achilefu, ... Biomaterials 73, 70-84, 2015 | 145 | 2015 |
| Cell trafficking of endothelial progenitor cells in tumor progression P De La Puente, B Muz, F Azab, AK Azab Clinical Cancer Research 19 (13), 3360-3368, 2013 | 132 | 2013 |
| Advancements in tumor targeting strategies for boron neutron capture therapy MJ Luderer, P De La Puente, AK Azab Pharmaceutical Research 32, 2824-2836, 2015 | 116 | 2015 |
| Hypoxia promotes stem cell-like phenotype in multiple myeloma cells B Muz, P De La Puente, F Azab, M Luderer, AK Azab Blood cancer journal 4 (12), e262-e262, 2014 | 101 | 2014 |
| Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional in vitro models S Bhattacharya, K Calar, P de la Puente Journal of Experimental & Clinical Cancer Research 39 (1), 75, 2020 | 86 | 2020 |
| Molecularly targeted therapies in multiple myeloma P de la Puente, B Muz, F Azab, M Luderer, AK Azab Leukemia research and treatment 2014 (1), 976567, 2014 | 82 | 2014 |
| The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies B Muz, P De La Puente, F Azab, M Luderer, AK Azab Molecular Cancer Research 12 (10), 1347-1354, 2014 | 70 | 2014 |
| Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma C Federico, K Alhallak, J Sun, K Duncan, F Azab, GP Sudlow, ... Nature communications 11 (1), 6037, 2020 | 68 | 2020 |
| Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma P de la Puente, MJ Luderer, C Federico, A Jin, RC Gilson, C Egbulefu, ... Journal of Controlled Release 270, 158-176, 2018 | 65 | 2018 |
| Injectable hydrogels for localized chemotherapy and radiotherapy in brain tumors P de la Puente, N Fettig, MJ Luderer, A Jin, S Shah, B Muz, V Kapoor, ... Journal of pharmaceutical sciences 107 (3), 922-933, 2018 | 58 | 2018 |
| The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015; 3: 83–92 B Muz, P de La Puente, F Azab, AK Azab Epub 2016/10/25. doi: 10.2147/HP, 0 | 58 | |
| PI 3 KCA plays a major role in multiple myeloma and its inhibition with BYL 719 decreases proliferation, synergizes with other therapies and overcomes stroma‐induced resistance F Azab, S Vali, J Abraham, N Potter, B Muz, P de la Puente, M Fiala, ... British journal of haematology 165 (1), 89-101, 2014 | 57 | 2014 |
| Autologous fibrin scaffolds cultured dermal fibroblasts and enriched with encapsulated bFGF for tissue engineering P De La Puente, D Ludeña, A Fernández, JL Aranda, G Varela, J Iglesias Journal of biomedical materials research Part A 99 (4), 648-654, 2011 | 57 | 2011 |
| Leukemia inhibitory factor: an important cytokine in pathologies and cancer MM Jorgensen, P de la Puente Biomolecules 12 (2), 217, 2022 | 55 | 2022 |
| Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma P de la Puente, AK Azab European journal of haematology 98 (6), 529-541, 2017 | 48 | 2017 |
| Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia B Muz, P De La Puente, F Azab, IM Ghobrial, AK Azab Molecular Cancer Research 13 (2), 263-272, 2015 | 40 | 2015 |
| Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance B Muz, HD Kusdono, F Azab, P de la Puente, C Federico, M Fiala, R Vij, ... Leukemia & lymphoma 58 (12), 2916-2925, 2017 | 38 | 2017 |
| Selinexor overcomes hypoxia-induced drug resistance in multiple myeloma B Muz, F Azab, P de la Puente, Y Landesman, AK Azab Translational oncology 10 (4), 632-640, 2017 | 37 | 2017 |
